SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-173885"
 

Search: onr:"swepub:oai:DiVA.org:liu-173885" > Current use of inot...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007468naa a2200865 4500
001oai:DiVA.org:liu-173885
003SwePub
008210309s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:145924573
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1738852 URI
0247 a https://doi.org/10.1186/s13613-021-00806-82 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1459245732 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Scheeren, Thomas W. L.u Univ Groningen, Netherlands4 aut
2451 0a Current use of inotropes in circulatory shock
264 c 2021-01-29
264 1b Springer,c 2021
338 a electronic2 rdacarrier
520 a BackgroundTreatment decisions on critically ill patients with circulatory shock lack consensus. In an international survey, we aimed to evaluate the indications, current practice, and therapeutic goals of inotrope therapy in the treatment of patients with circulatory shock.MethodsFrom November 2016 to April 2017, an anonymous web-based survey on the use of cardiovascular drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 14 questions focused on the profile of respondents, the triggering factors, first-line choice, dosing, timing, targets, additional treatment strategy, and suggested effect of inotropes. In addition, a group of 42 international ESICM experts was asked to formulate recommendations for the use of inotropes based on 11 questions.ResultsA total of 839 physicians from 82 countries responded. Dobutamine was the first-line inotrope in critically ill patients with acute heart failure for 84% of respondents. Two-thirds of respondents (66%) stated to use inotropes when there were persistent clinical signs of hypoperfusion or persistent hyperlactatemia despite a supposed adequate use of fluids and vasopressors, with (44%) or without (22%) the context of low left ventricular ejection fraction. Nearly half (44%) of respondents stated an adequate cardiac output as target for inotropic treatment. The experts agreed on 11 strong recommendations, all of which were based on excellent (> 90%) or good (81–90%) agreement. Recommendations include the indications for inotropes (septic and cardiogenic shock), the choice of drugs (dobutamine, not dopamine), the triggers (low cardiac output and clinical signs of hypoperfusion) and targets (adequate cardiac output) and stopping criteria (adverse effects and clinical improvement).ConclusionInotrope use in critically ill patients is quite heterogeneous as self-reported by individual caregivers. Eleven strong recommendations on the indications, choice, triggers and targets for the use of inotropes are given by international experts. Future studies should focus on consistent indications for inotrope use and implementation into a guideline for circulatory shock that encompasses individualized targets and outcomes.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Anestesi och intensivvård0 (SwePub)302012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Anesthesiology and Intensive Care0 (SwePub)302012 hsv//eng
653 a Acute circulatory failure; Sepsis; Septic shock; Cardiogenic shock; Resuscitation; Inotropes; Vasoactive agents; Catecholamines; Levosimendan; PDE-inhibitors; Cardiac output
7001 a Bakker, Janu NYU, NY USA; Columbia Univ, NY USA; Erasmus MC, Netherlands; Pontificia Univ Catolica Chile, Chile4 aut
7001 a Kaufmann, Thomasu Univ Groningen, Netherlands4 aut
7001 a Annane, Djillaliu Univ Paris Saclay, France4 aut
7001 a Asfar, Pierreu Angers Univ, France4 aut
7001 a Boerma, E. Christiaanu Med Ctr Leeuwarden, Netherlands4 aut
7001 a Cecconi, Mauriziou IRCCS Humanitas Res Hosp, Italy; Humanitas Univ, Italy4 aut
7001 a Chew, Michelleu Linköpings universitet,Avdelningen för klinisk kemi och farmakologi,Medicinska fakulteten,Region Östergötland, ANOPIVA US4 aut0 (Swepub:liu)micch61
7001 a Cholley, Bernardu Hop Europeen Georges Pompidou, France; Univ Paris, France4 aut
7001 a Cronhjort, Mariau Karolinska Institutet4 aut
7001 a De Backer, Danielu Univ Libre Bruxelles, Belgium4 aut
7001 a Dubin, Arnaldou Univ Nacl La Plata, Argentina; Sanatorio Otamendi, Argentina4 aut
7001 a Duenser, Martin W.u Kepler Univ Hosp, Austria; Johannes Kepler Univ Linz, Austria4 aut
7001 a Duranteau, Jacquesu Univ Paris Saclay, France4 aut
7001 a Gordon, Anthony C.u Imperial Coll London, England4 aut
7001 a Hajjar, Ludhmila A.u Univ Sao Paulo, Brazil4 aut
7001 a Hamzaoui, Olfau Paris Saclay Univ Hosp, France4 aut
7001 a Hernandez, Glennu Pontificia Univ Catolica Chile, Chile4 aut
7001 a Kanoore Edul, Vaninau Hosp Fernandez, Argentina4 aut
7001 a Koster, Geertu Univ Groningen, Netherlands4 aut
7001 a Landoni, Giovanniu Univ Vita Salute San Raffaele, Italy4 aut
7001 a Leone, Marcu Aix Marseille Univ, France4 aut
7001 a Levy, Brunou Univ Lorraine, France4 aut
7001 a Martin, Claudeu Aix Marseille Univ, France4 aut
7001 a Mebazaa, Alexandreu Univ Paris Diderot, France4 aut
7001 a Monnet, Xavieru Paris Saclay Univ Hosp, France; FHU SEPSIS, France4 aut
7001 a Morelli, Andreau Sapienza Univ Rome, Italy4 aut
7001 a Payen, Didieru Univ Paris 07, France; INSERM 1160, France; Hop Lariboisiere, France4 aut
7001 a Pearse, Rupert M.u Queen Mary Univ London, England4 aut
7001 a Pinsky, Michael R.u Univ Pittsburgh, PA USA4 aut
7001 a Radermacher, Peteru Univ Klinikum Ulm, Germany4 aut
7001 a Reuter, Daniel A.u Rostock Univ, Germany4 aut
7001 a Sakr, Yasseru Uniklinikum Jena, Germany4 aut
7001 a Sander, Michaelu Justus Liebig Univ Giessen, Germany4 aut
7001 a Saugel, Berndu Univ Med Ctr Hamburg Eppendorf, Germany4 aut
7001 a Singer, Mervynu UCL, England4 aut
7001 a Squara, Pierreu Clin Ambroise Pare, France4 aut
7001 a Vieillard-Baron, Antoineu Univ Hosp Ambroise Pare, France; Univ Versailles St Quentin Yvelines, France4 aut
7001 a Vignon, Philippeu Teaching Hosp Limoges, France; Univ Limoges, France4 aut
7001 a Vincent, Jean-Louisu Univ Libre Bruxelles, Belgium4 aut
7001 a van der Horst, Iwan C. C.u Maastricht Univ, Netherlands4 aut
7001 a Vistisen, Simon T.u Aarhus Univ, Denmark; Aarhus Univ Hosp, Denmark4 aut
7001 a Teboul, Jean-Louisu Paris Saclay Univ Hosp, France; FHU SEPSIS, France4 aut
7102 a Univ Groningen, Netherlandsb NYU, NY USA; Columbia Univ, NY USA; Erasmus MC, Netherlands; Pontificia Univ Catolica Chile, Chile4 org
7730 t Annals of Intensive Cared : Springerg 11:1q 11:1x 2110-5820
8564 u https://liu.diva-portal.org/smash/get/diva2:1535924/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://annalsofintensivecare.springeropen.com/track/pdf/10.1186/s13613-021-00806-8
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-173885
8564 8u https://doi.org/10.1186/s13613-021-00806-8
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:145924573

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view